Bristol Myers Squibb (BMY) Common Equity (2009 - 2026)

Bristol Myers Squibb has disclosed Common Equity across 18 years of filings, most recently posting $20.1 billion for Q1 2026.

• In Q1 2026, Common Equity rose 24.81% year-over-year to $20.1 billion; the TTM figure through Mar 2026 stood at $20.1 billion (up 24.81% YoY), while the FY2025 annual figure was $18.5 billion, up 24.1% from the prior year.
• Common Equity climbed to $20.1 billion in Q1 2026, from $18.5 billion in the prior quarter.
• Over the last five years, Common Equity for BMY reached as high as $46.1 billion in Q2 2025 and fell as low as -$43.7 billion in Q2 2024.
• The 5-year median for Common Equity is $16.1 billion (2025), against an average of $15.1 billion.
• Annual changes were most pronounced in 2023 — Common Equity jumped 80047.37% — and 2024, when it sank 196.45%.
• A 5-year view of Common Equity shows it stood at $57.0 million in 2022, then jumped by 80047.37% to $45.7 billion in 2023, then tumbled by 67.36% to $14.9 billion in 2024, then increased by 24.1% to $18.5 billion in 2025, then advanced by 8.62% to $20.1 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $20.1 billion, $18.5 billion, and $18.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.